Exclusive: Eisai's new oncology drug data shows focus on quality of life for cancer patients

30 September 2015

"Prolonging life is the gold standard endpoint of any drug trial," Professor John Crown, consultant medical oncologist for St Vincent’s University Hospital told The Pharma Letter in an interview, as the Japanese pharmaceutical firm Eisai (TYO: 4523) announced data for its clinical trials at the European Cancer Congress in Vienna.

Studies for Eisai's portfolio of drugs to treat different forms of cancer have shown significant improvement in overall survival.

“At the moment there are no real choices that meaningfully prolong survival,” Petra Rietschel, director of global medical affairs in oncology for Eisai said, while presenting the data for eribulin and lenvatinib.

Eribulin: breast cancer

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK